方泉
方 泉，男，二级教授，博士生导师，现任基础医学院副院长、医学生理学与心理学研究所所长2002年本科毕业于兰州大学生物学国家基地班，2007年博士毕业留校从事科研教学工作，2014年晋升为教授。2014年在美国杜克大学医学中心从事为期1年的访问学者研究。
主要从事神经肽类新药研究，先后入选教育部“青年长江”、甘肃省“飞天学者”青年学者和教育部“新世纪优秀人才”。主持各类科研课题近20项，其中国家自然科学基金4项、甘肃省创新群体项目1项。
以一作或通讯作者（含共同）在J Med Chem （含封面文章）、Br J Pharmacol等SCI期刊上发表的论文40篇。
已申请美国专利1件、国家发明专利15件（授权10件）、国际PCT专利2件；所研发的镇痛候选药物的部分成果已成功转化并用于原创性新药研发。研究成果曾获国家技术发明奖二等奖（排名第三），教育部科技进步一等奖(排名第五)，甘肃省技术发明一等奖(排名第二)，中国药学会科学技术一等奖(排名第二)。
2021年，入选兰州大学“萃英学者”（三级岗） ，2020年，甘肃省基础研究创新群体负责人 ，2019年，入选甘肃省“飞天学者”特聘计划（青年学者），2013年，入选教育部“新世纪优秀人才支持计划”（药学领域），2016年，国家技术发明奖二等奖（第三完成人）， 2016年，教育部科技进步奖一等奖（第五完成人），2013年，中国药学会科学技术奖一等奖（第二完成人），2011年，甘肃省技术发明一等奖（第二完成人），2017年，兰州大学“青年五四奖章”，2015年，全国药物化学学术会议暨第五届中英药物化学学术会议“青年学者优秀报告奖”，2011年，第十一届张锡均基金全国青年优秀生理学学术论文优秀奖（中国生理学会），2011年，第十一届全国多媒体课件大赛决赛三等奖（第六完成人）。
科研方向：
1. 神经肽生理与药理：神经肽是机体内一类重要的神经递质/调质，本实验室利用不同效能和效价的肽类分子作为药理学工具，来探讨内源性神经肽及其受体系统的生理学和药理学功能及其作用机制。
2. 神经肽与疼痛/痒觉 ：神经肽在躯体感觉的传导和调节中扮演重要的角色，本课题组利用分子、细胞和行为等多种研究手段来探讨神经肽在痛觉和痒觉调节过程中的作用及其具体机制。
3. 神经肽类新药创制：在神经肽结构和功能的研究基础上，以具有医药应用前景的内源性神经肽为化学模板而构建一系列的全新的肽类分子，以期筛选并获得具有高效、低副作用、镇痛（或止痒）类多肽药物的先导化合物用于多肽新药的研发。
主持的科研项目：1.主持甘肃省基础研究创新群体项目（20JR5RA310），原创性神经肽类镇痛新药创制，2020.11-2023.10；2.主持国家自然科学基金委面上项目（81973159），具有口服镇痛活性的阿片/神经肽FF受体多靶点环肽分子的设计和合成及其药理学鉴定，2020.1-2023.123.主持国家自然科学基金委面上项目（81673282），以神经肽为模板的大麻/神经肽FF受体多靶点分子的化学构建和无耐受镇痛作用研究，2017.1-2020.124.主持兰州大学“中央高校基本科研业务费专项资金”杰出人才项目（lzujbky-2018-ot02），神经肽类新药研究，2018.1-2019.125.主持国家自然科学基金委面上项目（81273355），阿片/神经肽FF 受体的双功能肽类配体的化学构建及其无耐受镇痛特性的研究，2013.1-2016.126.主持兰州大学“中央高校基本科研业务费专项资金”自由探索项目（lzujbky-2017-12），阿片肽对炎症痛和神经痛的调节及其分子机制研究，2017.1-2018.127.主持兰州大学“中央高校基本科研业务费专项资金”面上项目（lzujbky-2016-58），神经肽FF系统对痒觉的调节及其作用机制研究，2016.1-2017.68.主持兰州大学“中央高校基本科研业务费专项资金”重点项目（lzujbky-2014-k02），内源性大麻肽类配体的镇痛作用机制研究及其在镇痛新药研究中的应用，2014.1-2015.129.主持教育部“新世纪优秀人才支持计划”项目（NCET-13-0257），2014.1-2016.1210.主持兰州大学“中央高校基本科研业务费专项资金”重点项目（lzujbky-2014-k02），内源性大麻肽类配体的镇痛作用机制研究及其在镇痛新药研究中的应用，2014.1-2015.1211.主持甘肃省青年科技研究基金项目一项（1208RJYA001），以神经肽FF和阿片肽为模板的嵌合肽构建及其在镇痛用新药研究中应用，2013.1-2015.1212.主持兰州大学“中央高校基本科研业务费专项资金”自由探索项目（lzujbky-2013-167），内源性大麻肽类配体的生物活性鉴定，2013.1-2014.613.主持国家自然科学基金委青年基金项目（20902041），环境敏感性荧光氨基酸在新型NPFF1和NPFF2高选择性配体的设计和合成中的应用，2010.1-2012.1214.主持教育部高校博士点专项科研基金（新教师基金课题）（200807301028）, RFa肽家族的新成员——促摄食肽26RFa的构效关系及其生物活性的研究，2009.1-2011.1215.主持兰州大学“中央高校基本科研业务费专项资金”自由探索项目（LZUJC2007006），神经肽FF对大麻系统生物活性的调节，2010.7-2012.616.主持兰州大学“交叉学科青年创新研究”LZUJC2007006）基于MOR-NPFF2异源二聚体的双功能配体的化学合成及其生物活性研究，2008.1-2010.417.主持兰州大学博士启动基金一项 。
参与的科研项目情况：
1. 以项目组主要成员（4/11）参与十二五“重大新药创制”国家科技重大专项项目一项（2012ZX09504001-003），化学构建新型荧光标记神经肽配体的关键技术及其在G蛋白偶联受体靶向新药研究中应用，2012.1-2015.12
2. 以项目组主要成员（3/10）参与国家自然科学基金委——重点项目一项（20932003），具有重要医药用途的神经肽的化学修饰及作用机制研究，2010.1-2013.123. 以项目组主要成员（3/19）参与十一五“重大新药创制”国家科技重大专项项目一项（2009ZX09503-017）, 若干多肽合成和化学修饰的新方法和关键技术及其在多肽药物产业开发中的应用，2009.1-2010.124. 以项目组主要成员（2/10）参与国家自然科学基金委——重大研究计划培育项目（90813012）和集成项目一项，基于神经肽而构建的两类新型配体在Mu阿片受体聚合体的信号转导和痛觉调节研究中的应用，2009.1-2011.12
发表论文（按年度）：Publications ORCID iD: https://orcid.org/0000-0003-0381-6796已发表的主要论著目录：
1. Zhang MN, Xu B, Li N, Zhang R, Zhang QQ, Shi XR, Xu KT, Xiao J, Chen D, Niu JD, Shi YH, Fang Q*. Development of Multifunctional and Orally Active Cyclic Peptide Agonists of Opioid/Neuropeptide FF Receptors that Produce Potent, Long-lasting Peripherally Restricted Antinociception with Diminished Side Effects. Journal of Medicinal Chemistry 2021; Accepted. (IF2020 = 7.446) 2. Zhang T, Zhang R, Xu B, Zhang M, Zhang Q, Li N, Qiu Y, Chen D, Xu K, Xiao J, Zhang N*, Fang Q*. Spinal endomorphins attenuate burn-injury pain in male mice by inhibiting p38 MAPK signaling pathway through the mu-opioid receptor. European Journal of Pharmacology. 2021; 903:174139. (IF2020 = 4.432)3. Zhang MN, Xu B, Li N, Liu H, Shi XR, Zhang QQ, Shi YB, Xu KT, Xiao J, Chen D, Zhu HW, Sun YL, Zhang T, Zhang R, Fang Q*. Synthesis and biological characterization of cyclic disulfide-containing peptide analogs of the multifunctional opioid/neuropeptide FF receptors agonist that produced long-lasting and nontolerant antinociception.Journal of Medicinal Chemistry 2020; 63(24), 15709-15725. (IF2020 = 7.446, 封面文章)4. Xu B, Xiao J, Xu KT, Zhang QQ, Chen D, Zhang R, Zhang MN, Zhu HW, Niu JD, Zheng T, Li N, Zhang XY, Fang Q*. VF-13, a chimeric peptide of VD-hemopressin(α) and neuropeptide VF, produces potent antinociception with reduced cannabinoid-related side effects. Neuropharmacology 2020; 175: 108178. (IF2020 = 5.250)5. Zhang R, Xu B, Zhang QQ, Chen D, Zhang MN, Zhao GH, Xu KT, Xiao J, Zhu HW, Niu JD, Li N*, Fang Q*. Spinal administration of the multi-functional opioid/neuropeptide FF agonist BN-9 produced potent antinociception without development of tolerance and opioid-induced hyperalgesia. European Journal of Pharmacology. 2020; 880: 173169. (IF2020 = 4.432)6. Xu B, Guo YY, Zhang MN, Zhang R, Chen D, Zhang QQ, Xiao J, Xu KT, Li N, Qiu Y, Zhu HW, Niu JD, Zhang XY*, Fang Q*. Central and peripheral modulation of gastrointestinal transit in mice by DN-9, a multifunctional opioid/NPFF receptor agonist. Neurogastroenterology & Motility. 2020; 32(8): e13848. (IF2020 = 3.598)7. Wang ZL, Xu B, Jiang CY, Zhang T, Zhang MN, Li N, Zhang QQ, Xu KT, Chen D, Xiao J, Fang Q*. Spinal DN-9, a peptidic multifunctional opioid/neuropeptide FF agonist produced potent nontolerance forming analgesia with limited side effects. Journal of Pain.2020; 21(3-4): 477-493. (IF2020 = 5.820) 8. Xu B, Zhang MN, Shi XR, Zhang R, Chen D, Chen Y, Wang ZL, Qiu Y, Zhang T, Xu KT, Zhang XY, Liedtke W*, Wang R*, Fang Q*. The multifunctional peptide DN-9 produced peripherally acting antinociception in inflammatory and neuropathic pain via mu and kappa opioid receptors. British Journal of Pharmacology. 2020; 177: 93-109. (IF2020 = 8.739) 9.Zhang T, Han Z, Shi X, Zhao W, Wang Z, Zhang R, Xu B, Zhang M, Zhang Q, Xiao J, Zhu H, Zheng T, Fang Q*. Discovery of two novel branched peptidomimetics containing endomorphin-2 and RF9 pharmacophores: Synthesis and neuropharmacological evaluation. Bioorganic & Medicinal Chemistry. 2019; 27: 630-643. (IF2020 = 3.641)10. 方泉，李宁，许彪，王锐* 多靶点肽类镇痛药物的研究进展，2019，43(10): 726-3711. Zhang T1, Zhang N1, Zhang R, Zhao WD, Chen Y, Wang ZL, Xu B, Zhang MN, Shi XR, Zhang QQ, Guo YY, Xiao J, Chen D, Fang Q*. Preemptive intrathecal administration of endomorphins relieves inflammatory pain in male mice via inhibition of p38 MAPK signaling and regulation of inflammatory cytokines. Journal of Neuroinflammation. 2018; 15: 320. (IF2020 = 8.322) (1: authors contributed equally to this work)12. Zhang T, Zhao WD, Zhang MN, Xu B, Shi XR, Zhang QQ, Guo YY, Xiao J, Chen D, Zheng T, Fang Q*. Analgesic activities of the mixed opioid and NPFF receptors agonist DN-9 in a mouse model of formalin-induced orofacial inflammatory pain. Peptides. 2018; 110C: 30-39. (IF2020 = 3.750)13. Chen C1, Xu B1, Shi XR, Zhang MN, Zhang QQ, Zhang T, Zhao WD, Zhang R, Wang ZL, Fang Q*. GpTx-1 and [Ala5, Phe6, Leu26, Arg28]GpTx-1, two peptide NaV1.7 inhibitors: analgesic and tolerance properties at the spinal level.
British Journal of Pharmacology. 2018; 175(20): 3911-3927 (IF2020 = 8.739) (1: authors contributed equally to this work)14. Li N, Han ZL, Xu B, Zhang MN, Zhang T, Shi XR, Zhao WD, Guo YY, Zhang QQ, Fang Q*. Systemic administration of the bifunctional opioid/neuropeptide FF receptors agonist BN-9 produced peripheral antinociception in preclinical mouse models of pain. European Journal of Pharmacology. 2018; 837: 53-63. (IF2020 = 4.432)15. Wang P, Zheng T,
Zhang MN, Xu B, Zhang R, Zhang T, Zhao WD, Shi XR,
Zhang QQ, Fang Q*.
Antinociceptive effects of the endogenous cannabinoid peptide agonist VD-hemopressin(β) in mice.
Brain Research Bulletin.
2018; 139:48-55. (IF2020 = 4.077)16. Zheng T1, Zhang R1, Zhang T, Zhang MN, Xu B, Song JJ, Li N, Tang HH, Wang P, Wang R*, Fang Q*. CB1 cannabinoid receptor agonist mouse VD-hemopressin(α) produced supraspinal analgesic activity in the preclinical models of pain.
Brain Research. 2018; 1680: 155-164. (IF2020 = 3.252)17. Zhang R, Xu B, Zhang MN, Zhang T, Wang ZL, Zhao G, Zhao GH, Li N, Fang Q*, Wang R*. Peripheral and central sites of action for anti-allodynic activity induced by the bifunctional opioid/NPFF receptors agonist BN-9 in inflammatory pain model.
European Journal of Pharmacology. 2017; 813:122-129. (IF2020 = 4.432)18. Zheng T, Zhang T, Zhang R, Wang ZL, Han ZL, Li N, Li XH, Zhang MN, Xu B, Yang XL, Fang Q*, Wang R*. Pharmacological characterization of rat VD-hemopressin(α), an α-hemoglobinderived peptide exhibiting cannabinoid agonist-like effects in mice.
Neuropeptides2017, 63: 83-90. (IF2020 = 3.286)19. Wang ZL, Pan JX, Song JJ, Tang HH, Yu HP, Li XH, Li N, Zhang T, Zhang R, Xu B, Zhang MN, Fang Q*, Wang R*. Structure-based optimization of multifunctional agonists for opioid and neuropeptide FF receptors with potent non-tolerance forming analgesic activities.
Journal of Medicinal Chemistry.
2016; 59(22):10198-10208.(IF2020 = 7.446)20. Yu HP, Zhang N, Zhang T, Wang ZL, Li N, Tang HH, Zhang R, Zhang MN, Xu B, Fang Q*, Wang R*. Activation of NPFF2 receptor stimulates neurite outgrowth in Neuro 2A cells through activation of ERK signaling pathway.Peptides. 2016; 86: 24-32. (IF2020 = 3.750)21. Li N1, Han ZL1, Wang ZL, Xing YH, Sun YL, Li XH, Song JJ, Zhang T, Zhang R, Zhang MN, Xu B, Fang Q*, Wang R*. BN-9, a chimeric peptide with mixed opioid and NPFF receptors agonistic properties, produces nontolerance-forming antinociception in mice.
British Journal of Pharmacology. 2016; 173(11): 1864-1880. (IF2020 = 8.739) (1: authors contributed equally to this work)22. Wang ZL1, Li N1, Wang P, Tang HH, Han ZL, Song JJ, Li XH, Yu HP, Zhang T, Zhang R, Xu B, Zhang MN, Fang Q*, Wang R*. Pharmacological characterization of EN-9, a novel chimeric peptide of endomorphin-2 and neuropeptide FF that produces potent antinociceptive activity and limited tolerance.
Neuropharmacology. 2016; 108: 364-372. (IF2020 = 5.250) (1: authors contributed equally to this work)23. Chen Y, Fang Q, Wang Z, Zhang JY, MacLeod AS, Hall RP, Liedtke WB*. Transient receptor potential vanilloid 4 ion channel functions as a pruriceptor in epidermal keratinocytes to evoke histaminergic itch.
Journal of Biological Chemistry. 2016; 291:10252-10262. (IF2020 = 5.157)24. Li XH1, Lin ML1, Wang ZL, Wang P, Tang HH, Lin YY, Li N, Fang Q*, Wang R*. Central administrations of hemopressin and related peptides inhibit gastrointestinal motility in mice.
Neurogastroenterology & Motility. 2016; 28: 891-899. (IF2020 = 3.598) (1: authors contributed equally to this work)25. Zhang XY, Chen Y, Li Lin, Qiao H, Wang R, Ni JM *, You JQ, Ma KK, Fan CC, Fang Q. Development and validation of a reversed phase liquid chromatographic method with fluorescence detection for the pharmacokinetic study of a new chimeric peptide. Analytical Methods. 2016; 8(12): 2620-2627. (IF2020 = 2.896)26. Pan JX1, Wang ZL1, Li N, Zhang N, Wang P, Tang HH, Zhang T, Yu HP, Zhang R, Zheng T, Fang Q*, Wang R*. Effects of neuropeptide FF and related peptides on the antinociceptive activities of VD-hemopressin(α) in naive and cannabinoid-tolerant mice. European Journal of Pharmacology. 2015; 767(C):119-125. (IF2020 = 4.432) (1: authors contributed equally to this work)27. Han ZL, Wang ZL, Li XH, Li N, Pan JX, Zheng T, Fang Q*, Wang R*. Neuropeptide VF enhances cannabinoid agonist WIN55,212-2-induced antinociception in mice.
Anesthesia & Analgesia. 2015; 121(5):1360-1368. (IF2020 = 5.108)28. Chen Y, Kanju P 2, Fang Q 2, Lee SH, Parekh PK, Lee W, Moore C, Brenner D, Gereau RW 4th, Wang F, Liedtke W*. TRPV4 is necessary for trigeminal irritant pain and functions as a cellular formalin receptor.
Pain. 2014; 155(12):2662-72. (IF2020 = 6.961) (2: authors contributed equally to this work)29. Han ZL1, Fang Q1, Wang ZL, Li XH, Li N, Chang XM, Pan JX, Tang HZ, Wang R*. Antinociceptive effects of central administration of the endogenous CB1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], a N-terminally extended hemopressin peptide.
Journal of Pharmacology and Experimental Therapeutics. 2014; 348(2): 316-323. (IF2020 = 4.030) (1: authors contributed equally to this work)30. Wang ZL1, Fang Q 1, Han ZL, Pan JX, Li XH, Li N, Tang HH, Wang P, Zheng T, Chang XM, Wang R*. Opposite Effects of Neuropeptide FF on Central Antinociception Induced by Endomorphin-1 and Endomorphin-2 in Mice.
PLoS One. 2014; 9(8): e103773. (IF2020 = 3.240)
(1: authors contributed equally to this work)31. Pan JX, Wang ZL, Li N, Han ZL, Li XH, Tang HH, Wang P, Zheng T, Fang Q*, Wang R*. Analgesic tolerance and cross-tolerance to the cannabinoid receptors ligands hemopressin, VD-hemopressin(α) and WIN55,212-2 at the supraspinal level in mice. Neuroscience Letters. 2014; 578: 187-191. (IF2020 = 3.046)32. Li XH1, Li N1, Wang ZL, Pan JX, Han ZL, Chang XM, Tang HH, Wang P, Wang R*, Fang Q*. The hypotensive effect of intrathecally injected (m)VD-hemopressin(α) in urethane-anesthetized rats. Peptides. 2014; 56(C): 45-51. (IF2020 = 3.750)33. Han ZL, Wang ZL, Tang HZ, Li N, Fang Q*, Li XH, Yang XL, Zhang XY, Wang R*. Neuropeptide FF attenuates the acquisition and the expression of conditioned place aversion to endomorphin-2 in mice.Behavioural Brain Research 2013; 248(1):51-56. (IF2020 = 3.332) 34. Sun YL, Zhang XY, He N, Sun T, Zhuang Y, Fang Q*, Wang KR, Wang R*. Neuropeptide FF activated ERK and NF kappa B signal pathways in differentiated SH-SY5Y cells. Peptides 2012; 38(1):110-117. (IF2020 = 3.750) 35. Li N 1, Han ZL 1, Fang Q*, Wang ZL, Tang HZ, Ren H, Wang R*. Neuropeptide FF and related peptides attenuates warm-, but not cold-water swim stress-induced analgesia in mice. Behavioural Brain Research 2012; 233(2): 428-433. (IF2020 = 3.332) 36. Fang Q, Han ZL, Li N, Wang ZL, He N, Wang R*. Effects of neuropeptide FF system on CB1 and CB2 receptors mediated antinociception in mice.
Neuropharmacology 2012; 62 (2): 855-864. (IF2020 = 5.250)37. Fang Q 1, Jiang TN 1, Li N, Han ZL, Wang R*. Central administration of neuropeptide FF and related peptides attenuate systemic morphine analgesia in mice. Protein &Peptide Letters 2011; 18(4): 403-409. (IF2020 = 1.890) (1: authors contributed equally to this work)38. Fang Q 1, Li N 1, Jiang TN, Liu Q, Li YL, Wang R*. Pressor and tachycardic responses to intrathecal administration of Neuropeptide FF in anesthetized rats. Peptides 2010; 31(4): 683-688.(IF2020 = 3.750) (1: authors contributed equally to this work)
39. Fang Q 1, Liu Q 1, Li N, Jiang TN, Li YL, Yan X, Wang R*. Cardiovascular effects of intravenous administered 26RFa, a novel RF-amide peptide ligand for GPR103, in anaesthetized rats. European Journal of Pharmacology 2009; 621(1-3): 61-66. (IF2020 = 4.432) (1: authors contributed equally to this work) 40. Fang Q, Wang YQ, He F, Guo J, Guo J, Chen Q, Wang R*. Inhibition of neuropeptide FF (NPFF)-induced hypothermia and anti-morphine analgesia by RF9, a new selective NPFF receptors antagonist. Regulatory Peptides 2008; 147(1-3): 45-51. (SCI, IF2008 = 2.276) 41. Fang Q, Zhang BZ, Wang R*. Progress in the structure-activity relationship studies of neuropeptide FF.
Progress in Chemistry 2007; 19: 1977-1985. (IF2020 = 1.172, Review, in Chinese) 42.F ang Q, He F, Wang YQ, Guo J, Zhang BZ, Chen Q, Wang R*. Pharmacological effects of the dansylated neuropeptide FF analogues on body temperature and morphine analgesia. Neuropeptides 2007; 41(5): 339-347. (IF2020 = 3.286) 43. Fang Q, Guo J, He F, Peng YL, Chang M, Wang R*. In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist. Peptides 2006; 27(9): 2207-2213. (IF2020 = 3.750) 44. Fang Q, Guo J, Peng YL, Chang M, He F, Chen Q, Wang R*. In vitro and in vivo studies of dansylated compounds, the putative agonists and antagonists on neuropeptide FF receptors. Peptides 2006; 27(6): 1297-1304. (IF2020 = 3.750)45. Fang Q, Guo J, Chang M, Chen LX, Chen Q, Wang R*. Neuropeptide FF receptors exert contractile activity via inhibition of nitric oxide release in the mouse distal colon. Peptides 2005; 26(5): 791-797. (IF2020 = 3.750)46. Chen LX , Fang Q, Chen Q, Guo J, Wang ZZ, Chen Y, Wang R. Study in vitro and in vivo of nociceptin/orphanin FQ(1-13)NH2 analogues substituting N-Me-Gly for Gly2 or Gly3. Peptides 2004; 25(8): 1349-1354. (IF2020 = 3.750) 47. Wang YQ, Guo J, Wang SB, Fang Q, He F, Wang R*. Neuropeptide FF receptors antagonist, RF9, attenuates opioid-evoked hypothermia in mice. Peptides 2008; 29(7): 1183-90. (IF2020 = 3.750) 48. Chen LX, Wang ZZ, Wu H, Fang Q, Chen Y, Guo J, Chen Y, Wang R*. Effects of nociceptin (13-17) in pain modulation at supraspinal level in mice. Neuroscience Letters 2002; 331(2): 95-98. (IF2020 = 3.046)49. Wang YQ, Wang SB, Ma JL, Guo J, Fang Q, Sun T, Zhuang Y, Wang R*. Neuropeptide FF receptor antagonist, RF9, attenuates the fever induced by central injection of LPS in mice. Peptides. 2011; 32(4): 702-706. (IF2020 = 3.750) 50. Sun YL, Zhang XY, Sun T, He N, Li JY, Zhuang Y, Fang Q, Wang R. The anti-inflammatory potential of neuropeptide FF in vitro and in vivo. Peptides 2013; 47:124-132. (IF2020 = 3.750)51. Sun YL, Sun T, Zhang XY, He N, Zhuang Y, Li JY, Fang Q, Wang KR, Wang R*. NPFF2 receptor is involved in the modulatory effects of neuropeptide FF for macrophage cell line. Protein & Peptide Letters 2014; 21(5): 490-502. (IF2020 = 1.890)52. Fang Q, Yang MJ，Li RD. Inhibitory effects of melation on the tumor in mice bearing S180. Chinese Pharmacological Bulletin 2003; 2: 234-235. (in Chinese) （国内核心）53. Fang Q, He F, Wang YQ, Chen Q, Wang R. Studies in vitro and in vivo of pharmacological activities of PFR(Tic)amide. Sciencepaper Online (http://www.paper.edu.cn) 2006 Nov. 30. （科技论文在线）54. 李 宁，方 泉*.RFa家族新成员26RFa/43RFa的研究进展. 中国科技论文在线, http://www.paper.edu.cn/index.php/default/releasepaper/content/201202-2, 2012- 02-01（科技论文在线，四星级论文）
参编书籍：王 锐，方 泉，张 伟。参编中国科协组织2012-2013年的《生物化学与分子生物学学科发展报告》的“多肽学科发展报告”部分——“多肽科学研究进展”，中国科学技术出版社。
代表性专利成果：1. 王 锐，方 泉，李 宁，韩政岚；“基于内吗啡肽2和神经肽FF的嵌合肽及其合成和应用”， 国家发明专利，授权号：ZL201110097843.4，申请日期：2011年4月19日；公 开 (公告) 号：
CN102206285A，公开(公告)日： 2011.10.05。授权日期：2013年2月13日2. 王 锐，方 泉，韩政岚，王子龙，李宁；“基于阿片肽Biphalin和神经肽FF的嵌合肽及其合成和应用”，国家发明专利，授权专利号：ZL201210098832.2，授权日期：2014年5月21日。已申请
国际专利，PCT/CN2013/0706113. 王 锐，方 泉，韩政岚，王子龙，李宁，李旭辉；“内源性大麻肽类激动剂(m)VD-Hpα在制备镇痛药物中的应用”，国家发明专利，授权专利号。
ZL201310087565.3，授权日期：2015年4月22日。4. 王 锐，方 泉，李 宁，韩政岚，王子龙；“基于内吗啡肽2和NPFF受体拮抗剂RF9的分叉型杂交肽及其合成方法和应用”，国家发明专利，专利号：
ZL201510123629.X，授权日期：2017年11月28日5. 王 锐，方 泉，王 沛，张 婷，王子龙，李宁；“基于内吗啡肽2或Biphalin的棕榈酰化修饰的阿片肽类似物及其合成和应用”， 国家发明专利，授权专利号：
ZL201510619850.4，授权日期：2018年5月1日